Development
Takeda Pharmaceutical Company Limited
TAK
$15.30
-$0.22-1.42%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -36.63% | -16.13% | 32.95% | 12.07% | -50.43% |
| Total Depreciation and Amortization | 1.10% | -0.04% | -2.35% | -4.57% | -3.48% |
| Total Amortization of Deferred Charges | -21.40% | -21.40% | -21.40% | -21.40% | -8.11% |
| Total Other Non-Cash Items | -84.94% | -80.91% | -91.48% | -91.58% | 247.96% |
| Change in Net Operating Assets | -679.43% | -46.29% | -109.07% | -132.90% | -89.48% |
| Cash from Operations | -35.56% | -18.59% | -20.79% | -27.99% | -22.12% |
| Capital Expenditure | -9.74% | -2.11% | 8.21% | 4.70% | 4.48% |
| Sale of Property, Plant, and Equipment | 422.23% | 394.41% | -53.88% | -54.07% | -66.69% |
| Cash Acquisitions | -- | -- | -- | -- | 100.00% |
| Divestitures | -71.99% | -71.99% | -71.97% | -75.33% | -94.17% |
| Other Investing Activities | -706.41% | -600.50% | -535.80% | -636.46% | 41.57% |
| Cash from Investing | -317.99% | -241.87% | -211.17% | -158.18% | -221.53% |
| Total Debt Issued | -- | 30.35% | 30.35% | -53.88% | -100.00% |
| Total Debt Repaid | 9.77% | -42.14% | 25.27% | 52.92% | 50.26% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 95.52% | 97.72% | 97.72% | 65.27% | 1.18% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 2.45% | 13.54% | 13.00% | 18.58% | 17.76% |
| Other Financing Activities | 50.97% | 41.51% | -10.04% | -8.42% | -6.79% |
| Cash from Financing | 70.84% | 19.38% | 47.51% | 45.97% | 34.17% |
| Foreign Exchange rate Adjustments | -67.39% | -85.94% | -71.53% | -28.90% | 9.72% |
| Miscellaneous Cash Flow Adjustments | 950.00% | -287.01% | -185.71% | -- | -- |
| Net Change in Cash | -1,409.57% | -315.45% | -2,432.68% | -107.10% | -118.54% |